Lipids and lipoproteins in women

Mayo Clinic Proceedings

Volumn 72, Issue 3, 1997, Pages 235-244

  O'Brien, Timothy ^a   Nguyen, Tu T ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN E; CHOLESTEROL; CHYLOMICRON; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; MEVINOLIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; POSTMENOPAUSE; REVIEW; RISK FACTOR; UNITED STATES;

EID: 0031462435     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/72.3.235     Document Type: Article

References (107)

1. Heart and Stroke Facts. Dallas: American Heart Association, 1992
2. Wenger NK. Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993: 329:247-256
3. Greenland P, Reicher-Reiss H, Goldbourt U, Behar S. Inhospital and 1-year mortality in 1,524 women after myocardial infarction: comparison with 4,315 men. Circulation 1991: 83:484-491
4. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111:383-390
5. Bell MR, Holmes DR Jr, Berger PB, Garratt KN, Bailey KR, Gersh BJ. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. JAMA 1993; 269:2091-2095
6. Loop FD, Golding LR. MacMillan JP, Cosgrove DM, Lytle BW, Sheldon WC. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol 1983; 1:383-390
7. Barrett-Connor E, Bush TL. Estrogen replacement and coronary heart disease. Cardiovasc Clin 1989; 19:159-172
8. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kännel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986; 256:2835-2838
9. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34:1345-1353
10. Erkelens DW. Apolipoproteins in lipid transport, an impressionist view. Postgrad Med J 1989; 65:275-281
11. Tytgat GN, Rubin CE, Saunders DR. Synthesis and transport of lipoprotein particles by intestinal absorptive cells in man. J Clin Invest 1971; 50:2065-2078
12. Mahley RW, Hussain MM. Chylomicron and chylomicron remnant catabolism. Curr Opin Lipidol 1991; 2:170-176
13. Blanchette-Mackie EJ, Scow RO. Sites of lipoprotein lipase activity in adipose tissue perfused with chylomicrons: electron microscope cytochemical study. J Cell Biol 1971; 51:1-25
14. LaRosa JC, Levy RI, Herbert P, Lux SE, Fredrickson DS. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 1970; 41:57-62
15. Hussain MM, Maxfield FR, Mas-Oliva J, Tabas I, Ji ZS, Innerarity TL, et al. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J Biol Chem 1991; 266:13936-13940
16. Elovson J, Chatterton JE, Bell GT, Schumaker VN, Reuben MA, Puppione DL, et al. Plasma very low density lipoproteins contain a single molecule of apolipoprotein B. J Lipid Res 1988; 29:1461-1473
17. Havel RJ. The formation of LDL: mechanisms and regulation. J Lipid Res 1984; 25:1570-1576
18. Jones AL, Hradek GT, Hornick C, Renaud G, Windler EE, Havel RJ. Uptake and processing of remnants of chylomicrons and very low density lipoproteins by rat liver. J Lipid Res 1984; 25:1151-1158
19. Goldstein JL, Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977; 46:897-930
20. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest 1990; 86:379-384
21. Tall AR. Plasma lipid transfer proteins. J Lipid Res 1986; 27:361-367
22. Shirai K, Barnhart RL, Jackson RL. Hydrolysis of human plasma high density Iipoprotein2 phospholipids and triglycérides by hepatic lipase. Biochem Biophys Res Commun 1981; 100:591-599
23. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. NEnglJMed 1995; 332:1758-1766
24. Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, Payne GH, Harlan WR. Cholesterol and heart disease in older persons and women: review of an NHLBI workshop. AnnEpidemiol 1992; 2:161-176
25. Eaker ED, Castelli WP. Coronary heart disease and its risk factors among women in the Framingham study. In:
26. Wenger NK, editor. Coronary Heart Disease in Women: Proceedings of an N.I.H. Workshop. New York: Haymarket-Doyma, 1987: 122-130
27. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79:8-15
28. Jacobs DR Jr, Mebane IL, Bangdiwala SI, Criqui MH, Tyroler HA (Lipid Research Clinics Program). High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990; 131:32-47
29. Brunner D, Weisbort J, Meshulam N, Schwartz S, Gross J, Saltz-Rennert H, et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year followup of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Am J Cardiol 1987; 59:1271-1276
30. Lapidus L, Bengtsson C, Lindquist O, Sigurdsson JA, Rybo E. Triglycérides-main lipid risk factor for cardiovascular disease in women? Acta Med Scand 1985; 217:481-489
31. Austin MA. Plasma triglycéride and coronary heart disease. Arterioscler Thromb 1991 ; 11:2-14
32. Castelli WP. The triglycéride issue: a view from Framingham. Am Heart J 1986; 112:432-437
33. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993; 153:2209-2216
34. Austin MA, King MC, Vranizan KM, Newman B, Krauss RM. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet 1988; 43:838-846
35. Krauss RM, Williams PT, Blanche PJ, Cavanaugh A, Holl LG, Austin MA. Lipoprotein subclasses in genetic studies: the Berkeley data set. Genet Epidemiol 1993; 10:523528
36. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917-1921
37. Austin MA, Mykkanen L, Kuusisto J, Edwards KL, Nelson C, Haffner SM, et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995; 92:1770-1778
38. Haffner SM, Mykkanen L, Stern MP, Paidi M, Howard BV. Greater effect of diabetes on LDL size in women than in men. Diabetes Care 1994; 17:1164-1171
39. Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM, Selby JV. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb 1994; 14:1940-1945
40. Slyper AH. Low-density lipoprotein density and atherosclerosis: unraveling the connection. JAMA 1994; 272:305-308
41. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495-506
42. Hokanson JE, Austin MA, Zambon A, Brunzell JD. Plasma triglycéride and LDL heterogeneity in familial combined hyperlipidemia. Arterioscler Thromb 1993; 13:427-434
43. Austin MA. Genetic and environmental influences on LDL subclass phenotypes. Clin Genet 1994; 46:64-70
44. Haffner SM, Mykkanen L, Valdez RA, Paidi M, Stern MP, Howard BV. LDL size and subclass pattern in a biethnic population. Arterioscler Thromb 1993; 13:1623-1630
45. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1988; 67:30-35
46. Austin MA. Epidemiologie associations between hypertriglyceridemia and coronary heart disease. Semin Thromb Hemost 1988; 14:137-142
47. Scanu AM, Lawn RM, Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991; 115:209-218
48. Dahlen GH. Lipoprotein (a) in relation to atherosclerotic diseases. Prog Clin Biol Res 1988; 255:27-36
49. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990; 301:1248-1251
50. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfussin N. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992; 69:1251 -1254
51. Cremer P, Nagel D, Mann H, Labrot B, Müller-Berninger R, Thiery J, et al. Ranking of Lp(a) as a cardiovascular risk factor: results from a 10-year prospective study. Excerpta Medica International Congress Series No. 1066, 1994: 903-907
52. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttarri M, Manninen V, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89:59-67
53. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270:2195-2199
54. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273:1269-1273
55. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74:758-765
56. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 1994; 90:1688-1695
57. Shewmon DA. Lipids, atherosclerosis, and the postmenopausal woman: a clinical perspective. Obstet Gynecol Clin North Am 1994 Jun; 21:337-355
58. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323:1375-1381
59. Colvin PL Jr, Auerbach BJ, Case LD, Hazzard WR, Applebaum-Bowden D. A dose-response relationship between sex hormone-induced change in hepatic triglycéride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism 1991; 40:1052-1056
60. Notelovitz M, Feldman EB, Gillespy M, Gudat J. Lipid and lipoprotein changes in women taking low dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Am J Obstet Gynecol 1989; 160:1269-1280
61. Speroff L, DeCherney A (Advisory Board for the New Progestins). Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993; 81:1034-1047
62. Bagshaw S. The combined oral contraceptive: risks and adverse effects in perspective. Drug Saf 1995; 12:91-96
63. McPherson K. Third generation oral contraception and venous thromboembolism: the published evidence confirms the Committee on Safety of Medicines' concerns [editorial]. BMJ 1996; 312:68-69
64. Stadel B V. Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 1981; 305:672-677
65. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989; 298:165-168
66. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319:1313-1317
67. Mammen EF. Oral contraceptives and blood coagulation: a critical review. Am J Obstet Gynecol 1982; 142:781-790
68. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. Past use of oral contraceptives and cardiovascular disease: a meta-analysis in the context of the Nurses' Health Study. Am J Obstet Gynecol 1990; 163:285-291
69. Adams MR, Clarkson TB, Koritnik DR, Nash HA. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril 1987; 47:1010-1018
70. Davidoff F, Tishler S, Rosoff C. Marked hyperlipidemia and pancreatitis associated with oral contraceptive therapy. N Engl J Med 1973; 289:552-555
71. Singh K, Viegas OA, Loke DF, Ratnam SS. Effect of Norplant implants on liver, lipid and carbohydrate metabolism. Contraception 1992; 45:141-153
72. Otubu JA, Towobola OA, Aisien AO, Ogunkeye OO. Effects of Norplant contraceptive subdermal implants on serum lipids and lipoproteins. Contraception 1993; 47:149159
73. Miller VT. Lipids, lipoproteins, women and cardiovascular disease. Atherosclerosis 1994; 108(Suppl):S73-S82
74. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/ Progestin Interventions (PEPI) trial. JAMA 1995; 273:199-208
75. Cheang A, Sitruk-Ware R, Samsioe G. Transdermal oestradiol and cardiovascular risk factors. Br J Obstet Gynaecol 1994; 101:571-581
76. Whitcroft SI, Crook D, Marsh MS, Ellerington MC, Whitehead MI, Stevenson JC. Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. Obstet Gynecol 1994; 84:222-226
77. Corson SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. IntJFertil 1993; 38:79-91
78. Wild RA. Estrogen: effects on the cardiovascular tree. Obstet Gynecol 1996; 87(Suppl):27S-35S
79. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102-1109
80. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health 1989; 43:173-178
81. Williams JK, Honore EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol 1994; 24:1757-1761
82. Rosano GMC, Sarrel PM, Chierchia SL, Morgagni GL, Gabriele M, Leonardo F, et al. Medroxyprogesterone but not natural progesterone reverses the beneficial effect of estradiol 17 upon exercise-induced myocardial ischemia [abstract]. Circulation 1996; 94(Suppl 1):I-18
83. Xiang J, Lam JYT. Progestins reverse the platelet-inhibitory effect of estrogens in postmenopausal women [abstract]. Circulation 1996; 94(Suppl 1):I-18
84. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990; 97:1080-1086
85. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54:74-79
86. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333-1339
87. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithell H, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99:821-828
88. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-461
89. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women (in two parts). Lancet 1992; 339:1-15; 71-85
90. McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ 1991; 303:435-437
91. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115:860-864
92. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994; 86:1534-1539
93. Shewmon DA, Stock JL, Abusamra LC, Kristan MA, Baker S, Heiniluoma KM. Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism 1994; 43:531-532
94. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389
95. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lesperance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1995; 92:2404-2410
96. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al (MARS Research Group). Coronary angiographie changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119:969-976
97. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al (Cholesterol and Recurrent Events Trial Investigators). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009
98. American College of Physicians. Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglycéride levels as screening tests for preventing coronary heart disease in adults. Ann Intern Med 1996; 124:515-517
99. LaRosaJC. Cholesterol agonistics. Ann Intern Med 1996; 124:505-508
100. Bradford RH, Downton M, Chremos AN, Langendorfer A, Stinnett S, Nash DT, et al. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med 1993; 118:850-855
101. LaRosa JC, Applegate W, Grouse JR III, Hunninghake DB, Grimm R, Knopp R, et al. Cholesterol lowering in the elderly: results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994; 154:529-539
102. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007-3012
103. Koskinen P, Kovanen PT, Tuomilehto J, Manninen V. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers. Arch Intern Med 1992; 152:90-96
104. Glueck CJ, Levy RI, Fredrickson DS. Norethindrone acetate, postheparin lipolytic activity, and plasma triglycerides in familial types I, III, IV and V hyperlipoproteinemia: studies in 26 patients and 5 normal persons. Ann Intern Med 1971; 75:345-352
105. Rail SC Jr, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med 1992; 231:653-659
106. Kushwaha RS, Hazzard WR, Gagne C, Chait A, Albers JJ. Type III hyperlipoproteinemia: paradoxical hypolipidemic response to estrogen. Ann Intern Med 1977; 87:517-525
107. Mahley RW, Rail SC Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal VLDL lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. Vol 11. 7th ed. New York: McGraw-Hill, 1995: 1953-1980